{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=C.+albicans",
    "query": {
      "intervention": "C. albicans"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=C.+albicans&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T00:37:56.297Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00282308",
      "title": "A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisone",
          "type": "DRUG"
        },
        {
          "name": "C. albicans",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus toxoid adsorbed booster vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "23-valent pneumococcal polysaccharide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Keyhole limpet hemocyanin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 103,
      "start_date": "2006-01-23",
      "completion_date": "2012-05-28",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-09-12T00:37:56.297Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00282308"
    },
    {
      "nct_id": "NCT00006113",
      "title": "Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant CD40-ligand",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon gamma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interleukin-4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous dendritic cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic tumor infiltrating lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tyrosinase peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candida albicans skin test reagent",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "1999-06",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2014-05-22",
      "last_synced_at": "2026-09-12T00:37:56.297Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006113"
    },
    {
      "nct_id": "NCT04320628",
      "title": "Randomized Double-Blind Controlled Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Wounds",
        "Acute Wounds"
      ],
      "interventions": [
        {
          "name": "AnaSept®",
          "type": "DEVICE"
        },
        {
          "name": "NSS",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "SerenaGroup, Inc.",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 25,
      "start_date": "2020-05-20",
      "completion_date": "2022-03-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-14",
      "last_synced_at": "2026-09-12T00:37:56.297Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04320628"
    },
    {
      "nct_id": "NCT00001542",
      "title": "Fluconazole Prophylaxis of Thrush in AIDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acquired Immunodeficiency Syndrome",
        "Candidiasis",
        "Oral Candidiasis"
      ],
      "interventions": [
        {
          "name": "fluconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 80,
      "start_date": "1996-07",
      "completion_date": "2001-11",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-09-12T00:37:56.297Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001542"
    },
    {
      "nct_id": "NCT00496197",
      "title": "Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Candidiasis"
      ],
      "interventions": [
        {
          "name": "Eraxis (anidulafungin)",
          "type": "DRUG"
        },
        {
          "name": "Diflucan (fluconazole)",
          "type": "DRUG"
        },
        {
          "name": "Vfend (voriconazole)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 282,
      "start_date": "2007-07",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2011-10-03",
      "last_synced_at": "2026-09-12T00:37:56.297Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00496197"
    },
    {
      "nct_id": "NCT05422144",
      "title": "Cleanser for Acute Wounds",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Wound"
      ],
      "interventions": [
        {
          "name": "Antimicrobial Skin & Wound Cleanser (AWC)",
          "type": "DEVICE"
        },
        {
          "name": "Antimicrobial Wound Gel (AWG)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Rochal Industries LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-01-01",
      "completion_date": "2025-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-09-12T00:37:56.297Z",
      "location_count": 1,
      "location_summary": "Fort Sam Houston, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05422144"
    },
    {
      "nct_id": "NCT02889159",
      "title": "Immunologic Profile of Chronically Photodamaged Skin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Photoaged Skin",
        "Normal Skin"
      ],
      "interventions": [
        {
          "name": "Candida albicans antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "histamine phosphate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "imiquimod 5% cream",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tape Stripping",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2016-06-06",
      "completion_date": "2023-02-23",
      "has_results": false,
      "last_update_posted_date": "2025-02-13",
      "last_synced_at": "2026-09-12T00:37:56.297Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02889159"
    },
    {
      "nct_id": "NCT02393417",
      "title": "Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Warts"
      ],
      "interventions": [
        {
          "name": "CANDIN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Nielsen BioSciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 243,
      "start_date": "2015-03",
      "completion_date": "2018-03",
      "has_results": true,
      "last_update_posted_date": "2019-06-04",
      "last_synced_at": "2026-09-12T00:37:56.297Z",
      "location_count": 15,
      "location_summary": "Fort Smith, Arkansas • Rogers, Arkansas • Encinitas, California + 11 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Needham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02393417"
    },
    {
      "nct_id": "NCT02996448",
      "title": "Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autosomal-dominant Hyper-IgE Syndrome"
      ],
      "interventions": [
        {
          "name": "NDV-3A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 3,
      "start_date": "2016-11-17",
      "completion_date": "2018-10-09",
      "has_results": true,
      "last_update_posted_date": "2020-06-30",
      "last_synced_at": "2026-09-12T00:37:56.297Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02996448"
    },
    {
      "nct_id": "NCT05216510",
      "title": "Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "TNX-2110",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TNX-2120",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TNX-2130",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CANDIN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diluent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 9,
      "start_date": "2022-01-07",
      "completion_date": "2022-09-17",
      "has_results": true,
      "last_update_posted_date": "2024-11-06",
      "last_synced_at": "2026-09-12T00:37:56.297Z",
      "location_count": 1,
      "location_summary": "Berlin, New Jersey",
      "locations": [
        {
          "city": "Berlin",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05216510"
    }
  ]
}